Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 759 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Lung cancer screening can’t leave anyone in the UK behind July 27, 2023 ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... May 10, 2023 Facing the future: “How can a 3-year old understand that her... January 12, 2022 Body Location May Influence Fate of Cells with Cancer-Causing Mutations April 29, 2022 Load more HOT NEWS Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour Can Cancer Prevention Be Better Integrated into Primary Care? Joining the dots: How our new research data strategy will unlock...
